Tildrakizumab long-term effectiveness
Research has shown high levels of effectiveness are maintained for 5 years and beyond with tildrakizumab (Ilumya), an interleukin-23 (IL-23) inhibitor. At 3- and 6-month follow-up appointments, patients generally report no major side effects and are very satisfied with this treatment. Research experience further shows that tildrakizumab has a favourable long-term safety record, including a low incidence of side effects. Clinical trials with tildrakizumab began in 2013, meaning there are patients who are still receiving ongoing treatment and maintaining their results. Proactive patient support programs are available to facilitate and optimize treatment success.
